Primary headaches and cognitive disorders — pathophysiologically associated and comorbidity conditions.
https://doi.org/10.31363/2313-7053-2018-2-97-103
Abstract
Primary headaches (migraine, tension-type headache and other primary headaches) cause 3% of all disability cases in adult population, fully decrease possibilities of social functioning. Te phenomenon of the central sensitization is one of the fundamental pathophysiological units of primary headaches. NMDA receptors are involved both in initiation and in maintaining of mechanisms of a long-term central sensitization. NMDA activation by glutamate play important role in the initiation of primary headaches. Cognitive impairment development also conducted with NMDA-excitotoxicity due to hyper excitability of NMDA receptors. Tus, it is evident that mechanisms of antinociceptive changes in primary headaches and development of a glutamate excitotoxicity are strongly interdependent. Relationship between somatic symptoms, such as headache in dementia and cognitive symptoms now is represented more widely than just a comorbidity. Te gravity of migraine, tension-type headache and severity of cognitive impairment are strongly connected. Tus, the reliable interrelation between development of primary headache and cognitive decrease is traced, considering a community of pathophysiological mechanisms that has important practical value due to possible correction by NMDA-antagonists. Memantine not only slows the progression of cognitive symptoms in dementia, but also signifcantly influences the frequency and expressiveness of primary headache.
About the Authors
D. A. Iskra
Military Medical Academy n.a. S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
V. Yu. Lobzin
Military Medical Academy n.a. S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
S. A. Kalygin
Military Medical Academy n.a. S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
References
1. Деменция. Информационный бюллетень N°362 // Всемирная организация здравоохранения. URL: http://www.who.int/mediacentre/factsheets/fs362/ru/ (Дата обращения: 21.07.2017 г.)
2. Гаврилова С.И., Колыхалов И.В., Федорова Я.Б., Калын Я.Б., Селезнева Н.Д., Самородов А.В., Мясоедов С.Н., Бокша И.С. Прогноз прогрессирования когнитивного дефицита у пожилых пациентов с синдромом мягкого когнитивного снижения при длительном лечении (3-летнее наблюдение). — Журнневрол и психиат. — 2013. — №113. — С. 45-53.
3. Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. — Nature Reviews Neurology. — 2011. — Vol.7. — P. 137-152.
4. Yang F-C, Lin T-Y, Chen H-J, Lee J-T, Lin C-C, Kao C-H Increased Risk of Dementia in Patients with Tension-Type Headache: A Nationwide Retrospective Population-Based Cohort Study. PLOS ONE. — 2016. — Vol.11. e0156097.
5. Fereshtehnejad S.M., Damangir S., Cermakova P., Aarsland D., Eriksdotter M., Religa D. Comorbidity profle in dementia with Lewy bodies versus Alzheimer’s disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry. -Alzheimers Res Ter. — 2014. — Vol.6. — P. 65.
6. Hagen K., Stordal E., Linde M., Steiner T.J., Zwart J.A., Stovner L.J. Headache as a risk factor for dementia: a prospective population-based study.—Cephalalgia.—2014.—Vol. 34.—P. 327-335.
7. Røttereng A.K.S, Bosnes O., Stordal E., et al. Headache as a predictor for dementia: Te HUNT Study. — Te Journal of Headache and Pain. — 2015. — Vol.16. — P. 89.
8. Осипова В.В. Первичные головные боли: диагностика, клиника, терапия: практическое руководство. — Москва: Мед. информ. агентство: Российское о-во по изучению головной боли. — 2014. — 329 с.
9. Morton R., Tyas S. Does a history of migraines increase the risk of Alzheimer’s disease or vascular dementia? — Alzheimers Dement. — 2012. — Vol.8. — P. 504.
10. Bigal M.E., Kurth T., Santanello N., et al. Migraine and cardiovascular disease: A population-based study. — Neurology. — 2010. — Vol.74. — P. 628-635.
11. Kruit M.C., van Buchem M.A., Launer L.J., Terwindt G.M., Ferrari M.D. Migraine is associated with an increased risk of deep white matter lesions, subclinical posterior circulation infarcts and brain iron accumulation: Te population-based MRI CAMERA-study. Cephalalgia : an international journal of headache. — 2010. — Vol.30. — P. 129-136.
12. Kurth T., Winter A.C., Eliassen A.H., Dushkes R., Mukamal K.J., Rimm E.B., Willett W.C., Manson J.E., Rexrode K.M. Migraine and risk of cardiovascular disease in women: prospective cohort study. BMJ. 2016. 353 : i2610
13. Goulart A.C., Santos I.S., Lotufo P.A., Benseñor I.M. Cephalalgia. Gender aspects of the relationship between migraine and cardiovascular risk factors: A cross-sectional evaluation in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). — 2015. — Vol.35. — P. 1103-1114.
14. Sacco S., Pistoia F., Degan D., Carolei A. Conventional vascular risk factors: their role in the association between migraine and cardiovascular diseases. — Cephalalgia. — 2015. — Vol.35. — P.146-164.
15. Gao Y.J., Ji R.R. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain.—Pharmacol Ter.—2010.—Vol.126.—P. 56-68.
16. Gao Y.J., Ji R.R. Targeting astrocyte signaling for chronic pain. Neurotherapeutics. 2010. Vol. 7(4). P. 482-493.
17. D’Mello R., Marchand F., Pezet S., McMahon S.B., Dickenson A.H. Perturbing PSD-95 interactions with NR2B-subtype receptors attenuates spinal nociceptive plasticity and neuropathic pain. MolTer. 2011. Vol. 19(10). P. 1780-1792.
18. Mantyh P.W., Koltzenburg M., Mendell L.M., Tive L., Shelton D.L. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology. 2011.Vol. 115(1). P. 189-204.
19. Лобзин, В.Ю. Комплексная ранняя диагностика нарушений когнитивных функций Журн. неврологии и психиатрии им. С.С. Корсакова. 2015. Т. 115, № 11. С. 72-79.
20. Huang L., Bocek M., Jordan J.K., Sheehan A.H. Memantine for the prevention of primary headache disorders. — Ann Pharmacother. — 2014. — Vol.48. — P. 1507-1511.
21. Lindelof K., Bendtsen L. Memantine for prophylaxis of chronic tension-type headache-a doubleblind, randomized, crossover clinical trial. Cephalalgia. 2009. Vol. 29(3). P. 314-21.
22. Spengos K., Teleritis C. and Paparrigopoulos T. Memantine and NMDA Antagonism for Chronic Migraine: A Potentially Novel Terapeutic Approach? Headache: Te Journal of Head and Face Pain. 2008. Vol. 48. P. 284–286.
23. Noruzzadeh R., Modabbernia A., Aghamollaii V., Ghaffarpour M, Harirchian MH, Salahi S, Nikbakht N, Noruzi N, Tafakhori A. Memantine for Prophylactic Treatment of Migraine Without Aura: A Randomized Double-Blind Placebo-Controlled Study. Headache. 2016. Vol. 56(1). P. 95-103.
24. Venturelli E., Rao R., Charles A. Memantine for prevention of cluster headache: a possible new treatment? J Headache Pain. 2010. Vol. 11(suppl 1):S63.
25. Искра Д.А., Фрунза Д.Н. Повторная транскраниальная магнитная стимуляция в лечении хронических головных болей напряжения. — Вестник Военно-медицинской академии им. С.М.Кирова. — 2012. — Т.39. — С.34–38.
26. Benussi A., Padovani A., Borroni B. Transcranial Magnetic Stimulation in Alzheimer’s Disease and Cortical Dementias. — J Alzheimers Dis Parkinsonism. — 2015. — Vol.5. — P.197.
27. DosSantos M.F., Ferreira N., Toback R.L., Carvalho A.C., DaSilva A.F. Potential Mechanisms Supporting the Value of Motor Cortex Stimulation to Treat Chronic Pain Syndromes. Front Neurosci. 2016. 10:18.
28. Kwok R.P.S., Lundblad J.R., Chrivia J.C., et al. Nuclear protein CBP is a coactivator for the transcription factor CREB. — Nature. — 1994. — Vol.370. — P. 223–226.
Review
For citations:
Iskra D.A., Lobzin V.Yu., Kalygin S.A. Primary headaches and cognitive disorders — pathophysiologically associated and comorbidity conditions. V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY. 2018;(2):97-103. (In Russ.) https://doi.org/10.31363/2313-7053-2018-2-97-103
Views:
826
Email this article 